Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + paclitaxel + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy regimen used primarily for HER2-positive breast cancer. It combines an anthracycline (doxorubicin), a taxane (paclitaxel), and dual HER2-targeted therapy (pertuzumab and trastuzumab). The combination provides synergistic effects in treating HER2-positive breast cancer. Trastuzumab binds to subdomain IV of the HER2 receptor, while pertuzumab binds to subdomain II, preventing HER2/HER3 heterodimerization and homodimerization. This dual blockade of HER2 signaling, combined with the cytotoxic effects of doxorubicin and paclitaxel, has shown improved efficacy compared to single-agent therapies.
02
Targets
TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on doxorubicin + paclitaxel + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + paclitaxel + pertuzumab + trastuzumab.